Pay in 4 interest-free payments of $7.36 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Both GLP-1 and GIP can protect synapses and cognition
Dosing & Reconstitution Guide Educational guide for reconstitution and weekly dosing Standard / Gradual Approach (3 mL = ~1.67 mg/mL) Route: Subcutaneous injection
Molecular Basis of Local Action The local effect of AOD 9604 injection is closely related to its molecular properties: Receptor specificity AOD 9604 has a high affinity for 3-AR and reduces systemic side effects
Blood 64(2):415-21, 1984
Current NHS eligibility criteria for semaglutide 2.4 mg (Wegovy) for weight management, according to NICE TA875, include: Body Mass Index (BMI) 35 kg/m with at least one weight-related comorbidity (such as type 2 diabetes, hypertension, dyslipidaemia, obstructive sleep apnoea) For people from certain high-risk ethnic groups (such as South Asian, Chinese, Black African, or African-Caribbean), lower BMI thresholds apply (typically reduced by 2.5 kg/m) Treatment must be prescribed within specialist weight management services only Treatment is limited to a maximum duration of 2 years Must be used as an adjunct to a reduced-calorie diet and increased physical activity Liraglutide 3 mg (Saxenda) availability varies significantly across NHS regions and is not routinely commissioned in many areas
US$ 23.34
US$ 21.16
US$ 25.72
US$ 29.50
US$ 27.19
US$ 22.42
US$ 27.47
US$ 29.08
US$ 24.76
US$ 26.08
US$ 29.86
US$ 27.33
